Your Source for Venture Capital and Private Equity Financings

VC-funded Company:

Arkuda Therapeutics
200 Arsenal Yards Blvd, Suite 220
Cambridge, MA 02472
Phone: 617-579-1306

Arkuda Therapeutics is a biotechnology company leveraging new insights into progranulin and lysosomal biology to develop medicines to change the trajectory of neurodegenerative disease. Arkuda's lead compounds aim to correct progranulin deficiency and lysosomal dysfunction in GRN-related frontotemporal dementia (FTD-GRN), a genetically-defined subtype of frontotemporal dementia caused by an autosomal dominant mutation in the GRN gene. Arkuda launched in November 2019 with $44 million from leading life science investors include Atlas Venture, Pfizer Ventures, funds managed by Tekla Capital Management LLC, and BioInnovation Capital.

Key Contact
Name
Gerhard Koenig
Title
CEO
E-Mail
Funding Events

Date
Amount
Type
Investors
Valuation
11/08/19 $44,000,000 Series A Atlas Venture
Pfizer Venture Investments
Tekla Capital Management
undisclosed
02/10/22 $64,000,000 Series B Atlas Venture
Cormorant Asset Management
Eli Lilly and Company
Mission BioCapital
Pfizer Venture Investments
Pivotal bioVenture Partners
Surveyor Capital
Tekla Capital Management
undisclosed